A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Group 1 - Soligenix is developing thermostabilized subunit vaccines, including SuVax™ and MarVax™, which have shown complete protection in non-human primate studies against filoviruses [2][10][27] - The company has received Orphan Drug Designation from the FDA for both Sudan ebolavirus and Marburg marburgvirus, providing market exclusivity and various financial benefits [5][13] - The thermostabilization technology allows vaccines to remain stable at ambient temperatures, facilitating easier distribution and use [2][20][27] Group 2 - The company is focused on rare diseases with unmet medical needs, with additional products in development for conditions like cutaneous T-cell lymphoma and inflammatory diseases [8][24] - Soligenix's vaccine programs are supported by government grants and contracts from agencies like NIAID and BARDA, enhancing its financial position [4][24] - The upcoming presentation at the ASM Microbe Conference will highlight the advantages of the company's vaccine technology compared to other platforms [10][11][26]